Archive | Clinical Trials

Novel PKC Inhibitor Trial to Expand Its Cohort of Patients With Solid Tumors

The FDA granted Fast Track designation to BDTX-189 for the treatment of adult patients with solid tumors harboring an allosteric HER2 mutation or an EGFR or HER2 exon 20 insertion who have progressed following previous treatment and for whom no satisfactory alternative treatments exist, Black Diamond Therapeutics announced in a press release.1

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Investigators Present Updated Results of the OpACIN Trial for Melanoma

Christian U. Blank, MD, PhD, medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the most recent data from the phase 1b OpACIN trial (NCT02437279) of ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with macroscopic stage III melanoma.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Nivolumab Plus Ipilimumab Extends TFS Over Nivolumab Alone in Advanced Melanoma

With extended follow-up, patients with advanced melanoma given nivolumab plus ipilimumab were shown to have a treatment-free survival (TFS) twice as long as those given nivolumab monotherapy, according to data presented at the virtual 2020 ASCO Annual Meeting.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Long-Term Benefit of Dabrafenib Plus Trametinib in Melanoma Confirmed in 5-Year Follow-Up of COMBI-AD Study

The long-term benefit of adjuvant dabrafenib (Tafinlar) plus trametinib (Mekinist) as treatment of patients with resected, stage III BRAF V600E/K-mutant melanoma were validated by 5-year data from the phase 3 COMBI-AD study, according to a presentation from the 2020 American Soceity of Clinical Oncology (ASCO) Virtual Scientific Program.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials